Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Someone on this board needs to communicate to this board via TD Ameritrade the market capitalization is 300,000.
Divide 300,000 by PPS .0035 = 87,000,000 o/s
This means if a CEO of another company bought 20,000,000 there is roughly only 42,000,000 in the float and o/s of 87,000,000
Meaning?
News will send this above a penny in no time. Look at all Pharma related MMJ stocks. All trading above .03 w/no product or revenue.
EAPH has
MMJ distribution
Viorra
XILIVE
3 times a charm
$EAPH
12k on the ask... lol looks like they are running out of money or shares trying to hold us down.
GLTY
L6
Is it time to get my moon boots back on?
All I see is Sky's Ahead
EAPH!! is like a no hitter that you don't want to talk about EM.
Shows how little it takes to move this thing!!!
Nice start to the day GO EAPH
I just read the same thing on another board. Go EAPH.
From another board. Could be HUGE!!!
EAPH and AXXE Pharma merge and establish Canadian Marijuana Distribution centers
.
Don't be surprised if these 2 companies collaborate with each other in Canada for Marijuana initiatives soon!
PPS of .003 not for long peeps...
.05-.10 imo on news
Eaph is the best thing since sliced bread!
Easton Pharmaceuticals is based in Toronto, Ontario, Canada with a manufacturing partner in a 100,000 sq. ft. FDA approved facility in New Jersey, United States.
Easton Pharmaceuticals is committed to providing safe and effective products. Testing protocol is extensive for all products. Third party, multi-centre clinical trials will be completed for all products to validate efficacy statements and to give consumers confidence in the products.
ViorraTM has completed and passed irritation, allergic reaction, oral toxicity and three year stability studies. ViorraTM has completed an Open Label Clinical Pilot Trial to evaluate the safety and efficacy of the product. Pre and post-menopausal women with pre-diagnosed sexual function disorder for the past five years tested ViorraTM. There were no adverse data reported during the study and collectively the subjects reported: Less genital pain during intercourse, more sexual attempts with their partner, increase in vaginal lubrication, higher incidence of orgasm, increased desire to engage in sexual activity and an overall increase in sexual satisfaction.
Where is the beef? EM
LOL sadly it is none of those numbers mentioned. AS I know that you know EAPH has a 1 million equity line of credit and is using it when needed. Guess we have to wait to next reporting cycle to know for sure which one of the many growth opportunities' they have started funding.
Let see some shares change hands here today.
GLTY
l6
Just cause numbers are on the books as debt doesn't mean it is due! Is a person insolvent because they owe 400k on their house and only have 150K in the bank???? NO!
This is all Junior College business 101.
AS for not getting all of 1 million is because they do not need it at the moment.
Just like a home equity line of credit.
SOOO $EAPH is not insolvent. Those are just the facts about the company.
GLTY
L6
Edit ... changed there to their incase grammar is more important then business acumen.
Don't forget the million dollars $EAPH can access
Not true Insolvency is the inability to pay debt.EAPH!
I am with you there... Bids UP!!
Starting out a little slow this morning. Nothing traded under .32 but we will see what the afternoon brings.
Time & Sales
Price Size Mkt Time
$0.0033 83,000 OTO 11:14:13
$0.0032 42,000 OTO 10:04:46
$0.0032 22,000 OTO 10:01:48
$0.0034 100,000 OTO 10:01:36
$0.0034 26,000 OTO 09:52:12
$0.0032 64,000 OTO 09:52:04
$0.0034 10,000 OTO 09:51:46
$0.0033 10,000 OTO 09:51:46
$0.0032 58,000 OTO 09:37:23
Go EAPH.
L6
Thanks for posting the facts. Eaph looking UP!
Eaph to 005 short term EM
We will be fine a lot of people grabbing shares at this level.
Let see where we are by the end of the week and into next.
GLTY
L6
I agree I think we have seen the lows for the day. Any news this week will be good news.
L6
3 minutes till we are supposed to open... Lets Roll....
EAPH$ number 4 on the hot boards...
This is great news. Still not the one that made me invest in this stock.
Just a cherry on top of what is now even larger potential.
GLTY
L6
EAPH Looking GREEN all DAY!!!
Eaph to the moon. EOM
Thanks for the cheapies. A few hidden MM's got some filed at 0028 for some reason.
GLTY
No one told me the new entry point. I'll see where this goes and buy more into the next uptick..
A lot of strong hands here holding the float. Chumps will and most likely have dried up..
All I see is up and feeble attempts to run out the tiny tiny amount of weak hands here is over.
Glta
L6
Not weee BUT WEEEEEEEEEEEE... EM
WEEEEEEEEE....... WEEEEEEEEE. :) EM
Hit 56 today. Seems thin on the ask.
Anyone have any idea why IHUB did not pick up this PR?
Nice paint job. Eom
The Hot List Shines on Day 1: BZTG delivered the Hot List subscribers 100% gains and is still…
http://www.livetradingnews.com/hot-list-shines-day-1-11801.htm?utm_source=feedburner&utm_medium=twitter&utm_campaign=Feed%3A+EbelingHeffernanLTN+%28Live+Stock+Trading+News%29#.Ukw9doZQGao
BZTG delivered the Hot List subscribers 100% gains and is still going after it first appeared on the Hot List.
BZTG is still in a decade long ditch but the merger is close to being done.
62's up! Go EAPH.
HOD Coming up!
Here we go EAPH on the move.
Topical Alprostadil for Female Sexual Arousal Disorder
Information source: VIVUS, Inc.
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
http://www.druglib.com/trial/48/NCT00324948.html
Condition(s) targeted: Sexual Dysfunction, Physiological
Intervention: Topical alprostadil (PGE-1) (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: VIVUS, Inc.
Official(s) and/or principal investigator(s):
Sam Teichman, MD, Study Director, Affiliation: Vivus Clinical Research Department
Muse (Alprostadil) - Current Clinical Trials
http://www.druglib.com/druginfo/muse/trials/
The Use of Prostaglandin E1 in Head and Neck Microsurgery [Recruiting]
Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention [Not yet recruiting]
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV [Recruiting]
Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF) [Not yet recruiting]
Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction [Not yet recruiting]
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure [Recruiting]
Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease [Recruiting]
Alprostadil in Macular Degeneration Study (AIMS) [Recruiting]
Evaluation of an Educational Program Associated With Exercises (EDEX) Before Total Knee Arthroplasty [Recruiting]
Sildenafil and Alprostadil in Treating Patients Undergoing Bilateral Nerve-Sparing Robotic-Assisted Prostatectomy for Nonmetastatic Prostate Cancer [Recruiting]
Alprostadil Continuous Intravenous Infusion in Bridging Cardiac Transplant in Severe Heart Failure Patients [Not yet recruiting]
Topical Alprostadil for Female Sexual Arousal Disorder [Completed]
Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder [Terminated]
Inhaled Prostacyclin for Adult Respiratory Distress Syndrome (ARDS) and Pulmonary Hypertension [Recruiting]
Users Study Of The Caverject Delivery System [Not yet recruiting]
Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris [Recruiting]
Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy [Recruiting]
Efficacy and Safety Study of Combined Oral and Injection Therapy for Erectile Dysfunction [Recruiting]
Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers on Hands [Recruiting]
Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer [Active, not recruiting]
Monitoring in CHF Study [Enrolling by invitation]
Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking [Completed]
Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor [Completed]
Misoprostol for Treatment of Postpartum Haemorrhage (PPH) in Home Births [Recruiting]
Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor [Recruiting]
Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol [Recruiting]
The Role of Uterine Artery Doppler Parameters in the Management of Retained Products of Conception. [Not yet recruiting]
Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy [Recruiting]
Misoprostol Treatment of Incomplete Abortion by Midwives and Physicians in Uganda [Recruiting]
IUD Insertion in Nulliparous Women [Recruiting]
Techniques to Improve Efficacy of Second Trimester Medical Termination [Recruiting]
Misoprostol for Non-Viable Pregnancies [Completed]
Assessment of the Functional Significance of Accessory Pudendal Arteries [Recruiting]
Sublingual Versus Vaginal Misoprostol for Labor Induction at Term [Completed]
A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death [Recruiting]
Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption [Recruiting]
Trial of Amelior for Treatment of Pain in Post-Operative Adult Patients [Completed]